Kronos Bio Inc reports results for the quarter ended in December - Earnings Summary

Kronos Bio

15/03/2023 21:53

* Kronos Bio Inc  KRON.OQ  reported a quarterly adjusted
loss
of 56 cents​​ per share for the quarter ended in December. The
mean expectation of five analysts for the quarter was for a loss
of 59 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Kronos Bio Inc's reported EPS for the quarter was a loss
of 56
cents​.
    * The mean earnings estimate of analysts had risen by
about 6.1%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Kronos Bio Inc shares had fallen by 1.9% this quarter.
    * The company reported a quarterly loss of $31.78 million.
    * Wall Street's median 12-month price target for Kronos Bio
Inc is
$10.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data
March 15 at 09:52 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2022      -0.59          -0.56          Beat
 Sep. 30 2022      -0.65          -0.57          Beat
 Jun. 30 2022      -0.69          -0.59          Beat
 Mar. 31 2022      -0.66          -0.65          Beat